Companies › Edgewood Oncology
1 active drug program in 3 registered trials: 3 Phase 1; Oncology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BTX-A51 | – | Phase 1 | Acute Myeloid Leukemia; Advanced Solid Tumor; Liposarcoma | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06414434 | BTX-A51 | Phase 1 | Liposarcoma | Oncology | Jan 2027 |
| NCT04243785 | BTX-A51 | Phase 1 | Acute Myeloid Leukemia | Oncology | Mar 2027 |
| NCT04872166 | BTX-A51 | Phase 1 | Advanced Solid Tumor | Oncology | May 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.